Mental Health Clinical Trials Market Report 2026

The mental health clinical trials market size has grown strongly in recent years. It will grow from $3.23 billion in 2025 to $3.52 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increasing prevalence of mental health disorders, expansion of pharmaceutical research pipelines, growing awareness of mental health conditions, rising clinical research funding, increasing use of standardized diagnostic criteria.

The mental health clinical trials market size is expected to see strong growth in the next few years. It will grow to $4.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing adoption of digital mental health interventions, rising investments in personalized psychiatry research, expansion of global mental health trial networks, growing regulatory support for innovative trial designs, increasing use of data-driven outcome assessment. Major trends in the forecast period include increasing adoption of decentralized clinical trial models, rising use of digital therapeutics in trials, growing integration of AI-based patient recruitment tools, expansion of remote patient monitoring in studies, enhanced focus on real-world evidence generation.

The increasing prevalence of mental health disorders is expected to drive the growth of the mental health clinical trials market going forward. Mental health disorders are conditions that substantially impact an individual’s emotions, thinking, behavior, and overall psychological functioning. The incidence of mental health disorders is rising due to increasing stress associated with modern lifestyles, including work-related pressures, social isolation, and constant digital connectivity. Mental health clinical trials play a critical role in advancing care by assessing the safety and effectiveness of new drugs, therapies, and behavioral interventions for mental health conditions. For instance, in May 2024, according to the American Psychiatric Association, a US-based non-profit organization, approximately 43% of adults in the United States reported feeling more anxious in 2024, up from 37% in 2023 and 32% in 2022. Therefore, the growing prevalence of mental health disorders is contributing to the expansion of the mental health clinical trials market.

Major companies operating in the mental health clinical trials market are increasingly emphasizing the development of innovative solutions, such as software-enhanced drug therapies, to improve treatment effectiveness, personalize patient care, and strengthen real-world therapeutic outcomes. Software-enhanced drug therapies combine conventional medications with clinically validated therapeutic software to enhance patient outcomes by personalizing treatment, improving adherence, and delivering real-time behavioral or symptom-management support. For example, in October 2024, Click Therapeutics Inc., a US-based digital therapeutics company, introduced Click SE, a new offering designed to advance software-enhanced drug therapies by integrating prescription software with pharmacotherapy to provide additional clinical benefits and enable novel endpoints in mental health clinical development. Click SE is a software-centric product family comprising regulated mobile and cloud-based applications built on Click’s AI-enabled digital therapeutics platform. It operates by delivering structured therapeutic programs, real-time symptom tracking, and medication-specific digital support intended to work synergistically with a co-prescribed drug. Distinct features include adaptive algorithms that tailor content based on patient response, integration pathways aligned with pharmacologic dosing schedules, and embedded metrics for objective clinical trial endpoints. Applications include augmentation of antipsychotics for negative symptoms, adjunctive therapy for depression, and support for substance use disorders.

In March 2025, Wysa, a US-based mental health technology company, partnered with April Health Inc. to integrate its AI coach into primary care settings. This collaboration is intended to expand access to mental health services, streamline patient support, and improve outcomes through continuous, technology-enabled care. April Health Inc. is a US-based digital behavioral health company that delivers evidence-based mental health care through primary care platforms.

Major companies operating in the mental health clinical trials market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials, Inc., Ergomed, Celerion Inc., Biotrial S.A.S., Lindus Health Ltd., Novotech Health Holdings Pte Ltd., Precision for Medicine Inc.

North America was the largest region in the mental health clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mental health clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mental health clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the mental health clinical trials market by increasing costs associated with imported digital devices, wearable monitoring tools, data management platforms, and specialized research equipment used in decentralized and hybrid trial models. Clinical research organizations and sponsors in North America and Europe are most affected due to reliance on cross-border technology procurement, while Asia-Pacific faces higher costs for imported trial infrastructure. These tariffs are increasing operational expenses and extending study timelines. However, they are also encouraging local sourcing of digital trial tools, regional technology partnerships, and greater investment in domestic clinical research capabilities.

The mental health clinical trials market research report is one of a series of new reports that provides mental health clinical trials market statistics, including mental health clinical trials industry global market size, regional shares, competitors with a mental health clinical trials market share, detailed mental health clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the mental health clinical trials industry. This mental health clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mental health clinical trials are research studies designed to assess the safety, effectiveness, and overall impact of treatments, interventions, or diagnostic tools for mental health conditions. These trials may involve medications, psychotherapy, behavioral therapies, or digital tools, with the goal of improving mental health care by identifying effective methods to prevent, manage, or treat mental disorders.

The primary phases of mental health clinical trials include Phase I, Phase II, Phase III, and Phase IV. A Phase I clinical trial represents the initial stage of testing in humans for a new drug and focuses on evaluating safety, appropriate dosage, and potential side effects, typically involving 20 to 100 healthy volunteers. These trials employ various study designs, such as interventional, observational, and others, and address a range of disorders including anxiety disorders, depression, bipolar affective disorder, dissociative disorders, schizophrenia, and others. The key sponsors of these trials include pharmaceutical and biopharmaceutical companies, government agencies, and others.

The mental health clinical trials market includes revenues earned by entities through study design, patient recruitment, clinical monitoring, data management, regulatory consulting, site management, and statistical analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.